No, I'm sure you don't see anything because it's too obvious. Better to pretend and gaslight. Over the years the two companies have diverted due to good decision making vs. bad. But the two do have in common a single disease / single platform therapeutic product with a completed Plll waiting for regulators. One chose to remain on the Nasdaq while the other did not. One chose hundreds of employees while the other went with 20. One chose to fill all top management spots with highly qualified employees while the other has lawyers without employee agreements in place. Therefore one has an institutional following while the other has a CEO CFO Chair running a private CDMO who hasn't presented to her shareholders in five years. One raises $200M while the other raises $3M.
News 
Market Data 
Discover 
AI
